Bank of America sets USD 15.00 target for BioCryst stock
Published on 10/15/2026 at 21:39 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSAnalyst target and market position
- Bank of America Securities set a USD 15.00 target on October 9, 2026, 86.34 percent above the Nasdaq price.
- Second-quarter 2026 revenue reached USD 218.25 million, up 33.60 percent from the year-earlier quarter.
- BioCryst stock costs EUR 7.20 at Lang & Schwarz on October 15, 2026 at 9:35 p.m. CEST, unchanged versus the Nasdaq prior close of October 14, 2026.
- MarketBeat lists November 2, 2026 as the estimated next earnings date.
Bank of America Securities set a USD 15.00 price target for BioCryst Pharmaceuticals stock on October 9, 2026, according to Markets Insider. Against the Nasdaq price of USD 8.05 at 3:38 p.m. ET on October 15, 2026, the target stood 86.34 percent above the stock price. BioCryst stock was trading at EUR 7.20 at Lang & Schwarz on October 15, 2026 at 9:35 p.m. CEST, unchanged versus the Nasdaq prior close of October 14, 2026.
Revenue growth remains measurable
BioCryst reported USD 218.25 million in second-quarter 2026 revenue, up 33.60 percent from USD 163.35 million in the year-earlier quarter. Net income reached USD 78.40 million, compared with USD 5.09 million a year earlier, according to MarketBeat.
The result gives the analyst target a fundamental reference point, but the valuation picture remains mixed. The finance figures show a trailing P/E of minus 5.37, while the company paid no dividend. The market capitalization was USD 2.1 billion on October 15, 2026.
Price position and trading range
The Nasdaq price stood at USD 8.05 at 3:38 p.m. ET on October 15, 2026. The session range was USD 7.95 to USD 8.24, with 2,782,995 shares traded against an average volume of 4,083,987 shares. The 52-week range extended from USD 6.23 to USD 11.22, placing the price 28.22 percent above the low and 28.25 percent below the high.
BioCryst had formed a seven-member scientific advisory board on October 5, 2026, according to BioCryst. The company markets ORLADEYO for hereditary angioedema and is developing additional rare-disease therapies.
Valuation and next reporting date
MarketBeat lists November 2, 2026 as BioCryst's estimated next earnings date. Its analyst overview also records a USD 20.50 average target from 12 analysts, although that consensus is separate from the USD 15.00 Bank of America target.
Comparison with peers
BioCryst Pharmaceuticals (Nasdaq, USD): unchanged, P/E minus 5.37, market capitalization USD 2.1 billion
Ionis Pharmaceuticals (Nasdaq, USD): plus 3.40 percent, P/E minus 12.75, market capitalization USD 7.3 billion
Sarepta Therapeutics (Nasdaq, USD): plus 5.59 percent, P/E minus 6.14, market capitalization USD 1.9 billion
Trading closes near the middle of the range
The euro quote remained between its daily bid of EUR 7.17 and ask of EUR 7.22, while the US-listed price stayed closer to its 52-week low than its high. The next scheduled earnings date gives investors a defined calendar point for assessing whether the second-quarter revenue trend continues.
The further course of trading is shown by the continuously updated real-time quote of BioCryst Pharmaceuticals stock.
BioCryst market data
- Company: BioCryst Pharmaceuticals, Inc.
- ISIN: US09058V1035
- Ticker: BCRX
- Primary exchange: Nasdaq
- Price Lang & Schwarz (as of October 15, 2026, 9:35 p.m. CEST): EUR 7.20
- Change versus Nasdaq prior close: unchanged
- Market capitalization: USD 2.1 billion (as of October 15, 2026)
- 52-week range: USD 6.23-USD 11.22 (as of October 15, 2026)
- Sector / Industry: Healthcare / Biotechnology
- Next earnings date: November 2, 2026
Market context: Market report Nasdaq Composite.
